Navigation Links
Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care
Date:6/2/2008

Company's Report Entitled, 'Ingenuity at Work,' Discusses Abbott's Contributions to Access, Innovation, Science Education and the Environment

ABBOTT PARK, Ill., June 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today released its 2007 Global Citizenship Report, "Ingenuity at Work," which is available online at http://www.abbott.com/citizenship. The report highlights Abbott's commitment to access to care, innovation, science education and the environment.

Named to the Dow Jones Sustainability World and North American Indices in 2007 for the third consecutive year, Abbott remains a leader in economic, social and environmental performance -- with the company and the Abbott Fund contributing more than $385 million in grants and products to help improve the lives of millions of people around the world.

"To us, citizenship challenges are core business challenges -- they're part of how we effectively develop, manufacture and market a product," said Miles D. White, chairman and chief executive officer, Abbott. "We view citizenship as a matter of competitiveness and business discipline. We find it invigorating that society is demanding more of business enterprises today, and we're energized to meet and extend these new standards."
Following are some of Abbott's major accomplishments in 2007:

Access to Care

-- Provided support and resources to clinics and laboratories in Africa to

help people in need access medical care and supplies. Abbott plans to

help modernize 23 additional laboratories in Africa in 2010.

-- Offered more than $183 million worth of free Abbott medicines,

nutritionals and medical devices
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2
...er company says impact is ,significant and substan...lutant legislation, NEWARK, N.J., July 29 Eric S...th and safety, testified today before,Congress abo...known as CAIR). CAIR would have resulted in dramat...
...ticipants and spectators are reminded to protect t...rays on and off the field, PINELLAS PARK, Fla., J...gerly awaited time to enjoy outdoor sports and act...he summer,-- are conscious of the need to use sunb...
...A, Calif., July 29 On October 30, millions of bre... and loved ones will raise,their glasses in a "Toa... provides an opportunity for anyone,affected by br... cause advocates, thanking supporters, and showing...
...ferers Consider Veins a Cosmetic Issue Despite Exp... Discomfort, CHICAGO, July 29 Varicose veins -...y embarrassed sufferers to cover up, even on,the h...vey, many who suffer from varicose veins aren,t aw...
...Researchers at the University of Minnesota have fo...cognitive impairment in one of four child survivor...of the journal Pediatrics . , Malari...adliest forms of malaria. It only takes one bite f...
... RWSURVEY -- Web-Based Compliance Software Availab...unced the,release of its new web-based compliance ...w.rwsurvey.com ., The web-based software allows u...UA PCI HIPAA Compliance BSA-AML ISO 27001 Cob...
Other Medicine News:Health News:PSEG Supports Quick Congressional Action on Clean Air in Wake of Court's Rescinding of CAIR 2Health News:Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans 2Health News:Video: A 'Toast to the Cure' Set for October 30 Breast Cancer Survivors 'Raise Your Glasses' 2Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 2Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 3Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 4Health News:U of M researchers find cerebral malaria may be a major cause of brain injury in African children 2Health News:New Web-Based Compliance Program Released by RiskWatch 2
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
(Date:12/3/2009)HOERSHOLM, Denmark and SAN DIEGO, California, December 3 , - SPC3649 Successfully Inhibits miR-122, a microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatiti
(Date:12/3/2009)DURHAM, N.C., Dec. 3 In response to the increasingly critical role of healthcare information technologies in the evolving healthcare delivery system, Duke Medicine has created the Duke Center for Hea
Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3Surgeon Approved Pro Athlete Chiropractor Breaks the 2450 Billion Neck Pain Cycle With Launch of Pillo1 First Eco Luxe Neck Pillow 61153 1Surgeon Approved Pro Athlete Chiropractor Breaks the 2450 Billion Neck Pain Cycle With Launch of Pillo1 First Eco Luxe Neck Pillow 61153 2MinuteClinic Celebrates National Nurse Practitioner Week and Recognizes Role of Practitioners in Helping To Close Primary Care Gap 61151 1MinuteClinic Celebrates National Nurse Practitioner Week and Recognizes Role of Practitioners in Helping To Close Primary Care Gap 61151 2MinuteClinic Celebrates National Nurse Practitioner Week and Recognizes Role of Practitioners in Helping To Close Primary Care Gap 61151 3China Sky One Medical Inc Announces Conference Call to Discuss Third Quarter 2009 Results 14794 1China Sky One Medical Inc Announces Conference Call to Discuss Third Quarter 2009 Results 14794 2China Sky One Medical Inc Announces Conference Call to Discuss Third Quarter 2009 Results 14794 3
...ternational Conference of the American ... Forest Laboratories, Inc. and,Laboratorios Almir...al,trials assessing the efficacy and safety of acl...chronic obstructive pulmonary disease (COPD).,Data...the properties of,aclidinium were also presented a...
...ine and Synta,Pharmaceuticals Corp. (Nasdaq: SNTA... for elesclomol (formerly STA-4783), an investigat...c melanoma. A retrospective analysis,showed that s...elesclomol,and paclitaxel who had not previously r...nt improvement in progression-free survival (PFS),...
Other Medicine Technology:Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 2Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 3Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 4Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 5Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 2Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 3Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 4Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 5Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 6Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 7
MedLook 3.0
... Manager and Collections Administrator has a maxim...billing models and personalized paper or electroni...ty to facilitate rebilling, ledger notes, follow-u...en Collections Worksheet and efficient collection ...
...ware Associates medical billing and practice manag...ronically, while providing your practice with acco...e interface allows you to see insurance payments, ...ntage of services rendered. You can break these nu...
Infinity Amylase CNPG3 (Liquid)
Medicine Products: